Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) Trial

Circulation

Volumn 128, Issue 8, 2013, Pages 785-794

  Bach, Richard G ^a   Brooks, Maria Mori ^b   Lombardero, Manuel ^b   Genuth, Saul ^c   Donner, Thomas W ^d   Garber, Alan ^e   Kennedy, Laurence ^f   Monrad, E Scott ^g   Pop Busui, Rodica ^h   Kelsey, Sheryl F ^b   Frye, Robert L ⁱ  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

coronary disease; diabetes mellitus; myocardial infarction; pharmaceutical preparations; rosiglitazone; thiazolidinediones

Indexed keywords

HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; ANGIOPLASTY; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EXPOSURE; DRUG INTERACTION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; FRACTURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

CORONARY DISEASE; DIABETES MELLITUS; MYOCARDIAL INFARCTION; PHARMACEUTICAL PREPARATIONS; ROSIGLITAZONE; THIAZOLIDINEDIONES;

AGED; ANGIOPLASTY; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84882892659     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.000678     Document Type: Article

References (32)

1. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443
2. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med. 2007;12:311-318
3. Esposito K, Ciotola M, Carleo D, Schisano B, Saccomanno F, Sasso FC, Cozzolino D, Assaloni R, Merante D, Ceriello A, Giugliano D. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care. 2006;29:1071-1076
4. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004;93:362-365
5. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684
6. Yki-Järvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, Ehrenborg E, Eriksson P, Hamsten A. Regulation of plasma PAI-1 concentrations in HAART-Associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol. 2003;23:688-694
7. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004;24:930-934
8. Fang CC, Ng Jao YT, Yi-Chen, Yu CL, Chen CL, Wang SP. Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: A single center experience. Angiology. 2007;58:523-534
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471
10. Nissen SE, Wolski K. Rosiglitazone revisited: An updated meta-Analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191-1201
11. GlaxoSmithKline. FDA Advisory Committee briefing document: Cardiovascular safety of rosiglitazone. http://www.fda.gov/ohrms/dockets/ac/07/ briefing/2007-4308b1-01-sponsor-backgrounder.pdf. Accessed February 8, 2010
12. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: A meta-Analysis. JAMA. 2007;298:1189-1195
13. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298:2634-2643
14. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411-418
15. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147:578-581
16. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes -An interim analysis. N Engl J Med. 2007;357:28-38
17. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet. 2009;373:2125-2135
18. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim: Anti-diabetes medication to be taken off the market [press release]. London, UK: European Medicines Agency; September 23, 2010. http://www.ema. europa.eu/docs/en-GB/document-library/ Press-release/2010/09/WC500096996.pdf. Accessed December 14, 2012
19. US Food and Drug Administration Web site. FDA Safety Alert. Avandia (rosiglitazone): REMS: Risk of cardiovascular events. http://www.fda.gov/ safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ ucm226994.htm. September 23, 2010. Updated November 4, 2011. Accessed December 14, 2012
20. Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield J, Ramachandran A, Riddle M, Ryden LE, Zinman B, Afzal R, Yusuf S, Gerstein H. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia. 2012;55:36-45
21. US Food and Drug Administration Web site. FDA statement on Avandia TIDE Trial. http://www.fda.gov/Drugs/DrugSafety/ucm219780.htm. Updated July 21, 2010. Accessed December 14, 2012
22. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515
23. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol. 2006;97(12A):9G-19G
24. Brooks MM, Chaitman BR, Molitch ME; BARI 2D Study Group. Therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;361:1409-1410. Letter
25. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study. Diabetes Care. 2003;26:2983-2989
26. Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD. Heart failure events with rosiglitazone in type 2 diabetes: Data from the RECORD clinical trial. Eur Heart J. 2010;31:824-831
27. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-Associated fractures in type 2 diabetes: An Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31:845-851
28. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 2008;168:2368-2375
29. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-Analysis of randomised clinical trials. Lancet. 2007;370:1129-1136
30. Rosen CJ. The rosiglitazone story: Lessons from an FDA Advisory Committee meeting. N Engl J Med. 2007;357:844-846
31. Singh S, Loke YK. The safety of rosiglitazone in the treatment of type 2 diabetes. Expert Opin Drug Saf. 2008;7:579-585
32. Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet. 2009;373:2088-2090 Kidney Diseases Kidney Diseases Kidney Diseases Kidney Diseases